Back to search
FDAFDA · Food and drugs·Recall number D-0010-2019

Glipizide XL (glipizide) extended-release tablets 5 mg 500-tablet bottle, Rx only Distributed by: Greenstone LLC. Peapack, NJ 07977 --- NDC 59762-0541-2

Published October 17, 2018 · Recall initiated: September 20, 2018

Summary

FDA records drug Class II recall D-0010-2019, published October 17, 2018 and initiated September 20, 2018. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 7777 bottles; Lot: Lot: T71137 Exp. Feb. 2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations; rejected product was used to manufacture final bulk lot

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pfizer Inc.
Distributor
Nationwide
Lot
Lot: T71137 Exp. Feb. 2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glipizide XL (glipizide) extended-release tablets 5 mg 500-tablet bottle, Rx only Distributed by: Greenstone LLC. Peapack, NJ 07977 --- NDC 59762-0541-2 recalled?

Yes. FDA published recall D-0010-2019 on October 17, 2018. Reported hazard: CGMP Deviations; rejected product was used to manufacture final bulk lot

What should I do if I have this product?

Voluntary: Firm initiated · Letter